What is he best known for?
The fields of study he is best known for:
The scientist’s investigation covers issues in Antibody, Immunoglobulin light chain, Antigen, Biochemistry and Molecular biology.
His Antibody study incorporates themes from Periplasmic space and Cysteine.
His Immunoglobulin light chain research is multidisciplinary, incorporating elements of Protein engineering, Protein A and Immunoglobulin heavy chain.
While the research belongs to areas of Protein A, Paul Carter spends his time largely on the problem of Immunoglobulin Fc Fragments, intersecting his research to questions surrounding Amino acid and Stereochemistry.
His research in Antigen intersects with topics in Radioimmunotherapy, Internalization, Trastuzumab and Rituximab.
He works mostly in the field of Molecular biology, limiting it down to concerns involving Monoclonal antibody and, occasionally, Immunotherapy, Epidermal growth factor, Cell culture, Cancer and Clinical trial.
His most cited work include:
- Humanization of an anti-p185HER2 antibody for human cancer therapy. (2330 citations)
- A method for making heteromultimeric polypeptides (1493 citations)
- Method for making humanized antibodies (1267 citations)
What are the main themes of his work throughout his whole career to date?
Paul Carter mostly deals with Antibody, Biochemistry, Molecular biology, Stereochemistry and Immunology.
His study in Antibody is interdisciplinary in nature, drawing from both Cell culture, In vitro and Antigen.
Paul Carter has researched Molecular biology in several fields, including Receptor, Epidermal growth factor, Phage display and Monoclonal antibody.
His Monoclonal antibody research incorporates elements of Cancer and Immunotherapy.
His Stereochemistry research is multidisciplinary, relying on both Amino acid, Protein engineering, Substrate and Escherichia coli.
The concepts of his Immunology study are interwoven with issues in Cell, Cancer research and Computational biology.
He most often published in these fields:
- Antibody (52.23%)
- Biochemistry (23.57%)
- Molecular biology (23.57%)
What were the highlights of his more recent work (between 2012-2020)?
- Antibody (52.23%)
- Bispecific antibody (8.28%)
- Molecular biology (23.57%)
In recent papers he was focusing on the following fields of study:
Paul Carter mainly focuses on Antibody, Bispecific antibody, Molecular biology, Immunoglobulin light chain and Immunology.
His studies in Antibody integrate themes in fields like Biochemistry, Computational biology and Virology.
His Bispecific antibody research incorporates themes from Blinatumomab, Antigen, Antibodies monoclonal and Antibody-dependent cell-mediated cytotoxicity.
The Molecular biology study combines topics in areas such as Cell culture and In vitro.
His Immunoglobulin light chain study integrates concerns from other disciplines, such as Heavy chain, Orbitrap, Mass spectrometry, Protein engineering and Cell biology.
His research integrates issues of Intensive care medicine and Medical education in his study of Immunology.
Between 2012 and 2020, his most popular works were:
- Alternative molecular formats and therapeutic applications for bispecific antibodies. (426 citations)
- Next generation antibody drugs: pursuit of the 'high-hanging fruit'. (279 citations)
- The INNs and outs of antibody nonproprietary names. (42 citations)
In his most recent research, the most cited papers focused on:
His primary scientific interests are in Antibody, Bispecific antibody, Computational biology, Molecular biology and Drug development.
The Catumaxomab research Paul Carter does as part of his general Antibody study is frequently linked to other disciplines of science, such as Spatial relationship, therefore creating a link between diverse domains of science.
The various areas that Paul Carter examines in his Bispecific antibody study include Cell, In vitro, Antigen, Immunoglobulin light chain and Cell biology.
His work carried out in the field of Computational biology brings together such families of science as Antibody variable region, Immunology, Immune system, Antibody-dependent cell-mediated cytotoxicity and Blinatumomab.
His work on Monoclonal antibody as part of his general Immunology study is frequently connected to Scientific evidence, Expert group, Identity and Scientific literature, thereby bridging the divide between different branches of science.
His biological study spans a wide range of topics, including Antigen binding, Biochemistry, Nucleic acid, In vivo pharmacokinetics and Heavy chain.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
